BGNE May 2024 180.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.0500

-0.5100

(-91.07%)

As of 01:13PM EDT. Market open.

Loading interactive chart...

Zacks
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
Business Wire
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
SAN MATEO, Calif., May 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024. BeiGene has 28 abstracts accepted at EHA2024, with four scheduled for oral presentations.
Simply Wall St.
The BeiGene, Ltd. (NASDAQ:BGNE) First-Quarter Results Are Out And Analysts Have Published New Forecasts
A week ago, BeiGene, Ltd. ( NASDAQ:BGNE ) came out with a strong set of quarterly numbers that could potentially lead...